King et al. (38) and Carver et al. (39), confirmed this association in a murine model, both documenting that the development of invasive prostate cancer in double-transgenic models occurs at a higher rate than in ERG rearrangements or PTEN genomic deletions alone. The gene discussed is PTEN; the disease is prostate carcinoma.